Search for: "WYETH PHARMACEUTICALS COMPANY"
Results 501 - 520
of 547
Sorted by Relevance
|
Sort by Date
18 Jul 2008, 8:34 am
, (Daily Dose of IP), 11-12 September: US LSI: 4th annual conference on ‘Current issues in complex IP licensing’ – Philadelphia: (Patent Docs), 11 September/15 October: PLI seminar on developments in pharmaceutical and biotech patent law – New York/San Francisco: (Patent Docs), 15-16 September: UniForum & SAIIPL domain name ADR workshop – Centurion (South Africa): (Afro-IP), 15-16 September: US ACI 10th advanced forum on biotech… [read post]
7 Mar 2008, 2:00 am
: (IPBiz), US: Proposals for the approval of generic biologics under consideration: (Pharmacapsules@Gowlings), US: A paradigm shift in obviousness for pharma, biotech: (IP Law360), US: USPTO’s Bruce Kisliuk addresses ACI Pharma/biotech patent claim drafting and prosecution conference: (Patent Docs), US: New bill to provide biotech companies Sarbanes-Oxley relief: (California Biotech Law Blog), US: Biotech and pharma companies spent millions on lobbying… [read post]
4 Mar 2010, 10:58 am
It so happens that Indiana was on that list:Indiana: Ortho Pharmaceutical Corporation v. [read post]
27 Sep 2007, 11:38 am
Fujisawa Pharmaceutical Co., 464 F. [read post]
20 Dec 2007, 7:57 am
Despite the explicit rejection of such language, remarks by some Congressional opponents of preemption seemed more apropos to the draft legislation that contained the anti-preemption proviso rather than to the statute from which such language had been deleted.Several members of Congress stated that the 2007 Act expressly preserved what they considered to be the "balance of responsibility" between FDA and pharmaceutical companies to ensure full disclosure of health risks… [read post]
5 Jul 2008, 11:05 am
, (Daily Dose of IP), 11-12 September: US LSI: 4th annual conference on ‘Current issues in complex IP licensing’ – Philadelphia: (Patent Docs), 11 September/15 October: PLI seminar on developments in pharmaceutical and biotech patent law – New York/San Francisco: (Patent Docs), 15-16 September: UniForum & SAIIPL domain name ADR workshop – Centurion (South Africa): (Afro-IP), 15-16 September: US ACI 10th advanced forum on biotech… [read post]
15 Mar 2010, 2:09 pm
American Honda Motor Company, Inc. (2000) 529 U.S. 861, 868, 120 S.Ct. 1913, 146 L.Ed.2d 914) (National Highway Traffic Safety Administration) “[A] reading of the express pre-emption provision that excludes common-law tort actions gives actual meaning to the saving clause's literal language, while leaving adequate room for state tort law to operate-for example, where federal law creates only a floor, i.e., a minimum safety standard. [read post]
20 Jun 2008, 8:07 am
: (Spicy IP), Latin America: Merck Serono signs distribution agreement with Bristol-Myers Squibb for portfolio of established pharmaceutical brands in Latin America: (IP tango), US: Biotech industry growth to slow due to funding pressures and competition from biosimilars: (Managing Intellectual Property), US: House Commerce Committee posts responses to its questions on biogenerics; not surprisingly, the views run the gamut: (FDA Law Blog), US: Biosimilar debate heats up at BIO: (Managing… [read post]
10 Jan 2011, 1:55 pm
The opinion cites Wyeth v. [read post]
8 Jun 2012, 10:35 am
Wyeth Labs., 498 F.2d 1264, 1276 (5th Cir. 1974) omitted]. [read post]
19 Apr 2013, 5:35 pm
Wyeth Pharm. [read post]
14 May 2007, 7:03 am
Fujisawa Pharmaceutical Co., 464 F. [read post]
13 Jun 2008, 3:40 am
: (Patent Docs), Generic drug developers will continue to take advantage of global demand for lower-priced drugs, with Teva poised to maintain lead position says Goldman Sachs analyst: (GenericsWeb), Daiichi Sankyo takeover of Ranbaxy: (Profitability through Simplicity), (Spicy IP), (GenericsWeb), Canada: Generics to penetrate 26% pharma market in Canada says RNCOS research: (GenericsWeb), Canada: Generic drug makers spreading misinformation about patent regulation amendments to dodge real story:… [read post]
26 Feb 2015, 5:00 am
Merrell-Dow Pharmaceuticals, Inc., 523 A.2d 374 (Pa. [read post]
3 Apr 2009, 5:10 am
Cigna, like many other companies, is trying to rein in legal expenses. [read post]
26 May 2015, 7:42 am
SJS/TEN is somewhat analogous in our sandbox to mesothelioma in asbestos cases, since plaintiffs often work backwards from the diagnosis to look for some drug company to sue. [read post]
25 Jun 2014, 2:00 pm
Drakes Bay Oyster Company v. [read post]
2 Oct 2008, 12:36 pm
Astrazeneca Pharmaceuticals, LP, 500 F.Supp.2d 736 (S.D. [read post]
4 Jun 2009, 11:04 am
For instance, here's the response of "The Younger Lawyer" to Wyeth v. [read post]
17 Sep 2009, 4:30 am
Given the size of the overdose, no alleged illegibility of the little lines on the cup could possibly have made the slightest difference in the result.What's going on in those cases is the same thing we've already commented about in the context of the big preemption cases, Wyeth v. [read post]
